MAPT and Alzheimer disease: In CSF, increased levels of phosphorylated tau at residue 217 (p-tau217) and p-tau235 as well as p-tau231 are shown to be correlated with the early stages of AD [83], while p-tau181 can be used as a prognostic tool for the advanced phases of AD [84].